The Impact of Air Travel on Passenger Cognitive Functions
調査の概要
状態
条件
研究の種類
入学 (予想される)
段階
- フェーズ2
- フェーズ 3
連絡先と場所
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Study participants (Volunteers) will be recruited through media, advertisements and announcements. Prior to the study, study participants will receive written and oral explanations of the study protocols, and written informed consent will be obtained from each study participant. All potential research participants will undergo medical and psychological selection. The components, stages of selection are almost the same as those of general professional selection: the first stage is professiography / psychogram, the second stage is psychodiagnostics, the third stage is assessment and forecasting, and the fourth stage is decision making. Selection will assess the ability of participants to perform complex sequential actions.
Inclusion criterion:
- Age from 22 to 30 years old;
- at least 15 years of education, including secondary education;
- understand and speak Russian (Due to the valid Russian-language questionnaire and methodology).
In addition, study participants will be asked not to limit their caffeine intake from their daily intake, but only water is allowed 4 hours before the neuropsychological testing. Participants in the study should not hmedical/medicallane in the last two weeks prior to the start of the study, nor should they consume alcohol during the study.
Exclusion criterion:
- A member taking melatonin (affects circadian rhythm);
- Participant with comorbidities that affect cognitive function and sleep (eg, stroke, TIA, concussion with loss of consciousness, hearing problems, chronic fatigue syndrome, depression, seasonal affective disorder, anorexia);
- A participant with another ongoing sleep disorder.
All participants must be free of a history of venous thrombosis, antithrombotic or anticoagulant medications and oral contraceptives and / or any other drugs that interfere with blood coagulation (i.e. warfarin, coumadin) for at least 2 months prior to study initiation, and sign a consent to refrain from taking medications that may affect coagulation, such as aspirin or non-steroidal anti-inflammatory drugs, within 3 days after the flight, unless there is a medical / medical need.
-
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:防止
- 割り当て:ランダム化
- 介入モデル:並列代入
- マスキング:なし(オープンラベル)
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的:The study Group
|
Citicoline 500 mg (Vitaae®) per os
他の名前:
Cytochrome10 mg per os
他の名前:
Sodium Chloride (NaCl) 2.6 g. per os
Potassium Chloride 1.5 g per os
他の名前:
Sodium Citrate 2.90 g per os
他の名前:
Dextrose 13.5 g per os
他の名前:
Domperidone 1 tablet per os
他の名前:
3-4 capsules per os
他の名前:
Acetylsalicylic acid 150 mg per os
magnesium hydroxide 30 mg per os
1 capsule per os.
他の名前:
|
|
アクティブコンパレータ:Control group
Melatonin® 5 mg per os 2 hours before bedtime on the day of arrival for 3-4 days.
|
Melatonin 5 mg per os.
他の名前:
|
|
介入なし:Explanatory group:
12 participants without any intervention.
|
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Urine Specific Gravity
時間枠:24 hours before the flight
|
Urine Specific Gravity test
|
24 hours before the flight
|
|
SpO2 level
時間枠:24 hours before the flight
|
Pulse oximetry
|
24 hours before the flight
|
|
Ultrasound examination
時間枠:24 hours before the flight
|
Ultrasound examination of the veins of the lower limbs
|
24 hours before the flight
|
|
The Liverpool Jet Lag questionnaire
時間枠:24 hours before the flight
|
Changes from normal (0 to 5) while jetlag rating was recorded on a scale from 0 = insignificant jetlag to 10 = severe jetlag
|
24 hours before the flight
|
|
Lake Louise Acute Mountain Sickness Assessment System
時間枠:24 hours before the flight
|
Mild acute mountain sicknessas 3-5 points, moderate acute mountain sickness as 6-9 points, and severe acute mountain sickness as 10-12 points
|
24 hours before the flight
|
|
Neuropsychological tests (Trail Making Test, Wechsler Memory Scale - IV, Free recall
時間枠:24 hours after the flight
|
Word, color, and color-word T-Scores of 40 or less are considered "low."
Word, color, and color-word T-Scores above 40 or are considered "normal."
In order for one score to be considered "higher" or "lower" than another, a 10 point or greater T score difference is required.
|
24 hours after the flight
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
SpO2 level
時間枠:24 hours before the flight
|
Pulse oximetry
|
24 hours before the flight
|
|
The Liverpool Jet Lag questionnaire (LJLQ)
時間枠:24 hours after the flight
|
Changes from normal (0 to 5) while jetlag rating was recorded on a scale from 0 = insignificant jetlag to 10 = severe jetlag
|
24 hours after the flight
|
|
Lake Louise Acute Mountain Sickness Assessment System
時間枠:24 hours after the flight
|
Mild acute mountain sicknessas 3-5 points, moderate acute mountain sickness as 6-9 points, and severe acute mountain sickness as 10-12 points
|
24 hours after the flight
|
|
The Stroop Test
時間枠:24 hours after the flight
|
Word, color, and color-word T-Scores of 40 or less are considered "low."
Word, color, and color-word T-Scores above 40 or are considered "normal."
In order for one score to be considered "higher" or "lower" than another, a 10 point or greater T score difference is required.
|
24 hours after the flight
|
|
Urine Specific Gravity
時間枠:24 hours after the flight
|
Urine Specific Gravity test
|
24 hours after the flight
|
協力者と研究者
スポンサー
研究記録日
主要日程の研究
研究開始 (予想される)
一次修了 (予想される)
研究の完了 (予想される)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
追加の関連 MeSH 用語
- 薬の生理作用
- 神経伝達物質のエージェント
- 薬理作用の分子機構
- 中枢神経系抑制剤
- 自律神経剤
- 末梢神経系エージェント
- 酵素阻害剤
- 鎮痛剤
- 感覚系エージェント
- 抗炎症剤、非ステロイド
- 鎮痛剤、非麻薬性
- 抗炎症剤
- 抗リウマチ剤
- 線維素溶解剤
- フィブリン調節剤
- 血小板凝集阻害剤
- シクロオキシゲナーゼ阻害剤
- 解熱剤
- 制吐薬
- 胃腸薬
- 保護剤
- 皮膚科用薬
- ドーパミン剤
- ドーパミン拮抗薬
- 抗凝固剤
- 酸化防止剤
- 消泡剤
- 皮膚軟化剤
- キレート剤
- 隔離エージェント
- 向知性薬
- カルシウムキレート剤
- 制酸剤
- アスピリン
- メラトニン
- シメチコン
- 水酸化マグネシウム
- ドンペリドン
- クエン酸
- クエン酸ナトリウム
- シチジン二リン酸コリン
その他の研究ID番号
- 1 (Mobile Health and Wellness Program)
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。